Genomics services hold 38.4% share while next-generation sequencing accounts for 42.1%, highlighting the growing role of outsourced omics workflows in pharmaceutical research

ROCKVILLE, Md. — September 22, 2026 — The global omics lab services market is projected to increase from USD 75.1 billion in 2026 to USD 189.5 billion by 2036, expanding at a 9.7% CAGR during the forecast period, according to a new report by Fact.MR. The market was valued at USD 68.5 billion in 2025, with an estimated absolute opportunity of USD 114.4 billion between 2026 and 2036.

The market covers outsourced laboratory services spanning genomics, transcriptomics, proteomics, metabolomics, epigenomics, single-cell analysis, and multi-omics workflows. Pharmaceutical companies, biotechnology firms, research institutions, hospitals, and contract research organizations increasingly use specialist laboratories when building every sequencing, assay, and bioinformatics capability internally is not practical.

Get detailed market forecasts, competitive benchmarking, and pricing trends:https://www.factmr.com/connectus/sample?flag=S&rep_id=15767

Drug Discovery Creates a Major Source of Demand

Drug discovery and development is projected to account for 32.4% of market demand in 2026, making it the leading application segment. Omics services support target identification, lead optimization, biomarker discovery, mechanism-of-action studies, and patient stratification across development programs.

Pharmaceutical and biotechnology companies are expected to represent 30.5% of end-user demand in 2026. These organizations generate recurring project requirements across discovery and development stages and often require validated workflows, defined quality metrics, secure data handling, and reproducible results.

Outsourcing also allows research teams to access specialized sequencing and analytical capabilities without making equivalent investments in laboratory infrastructure and personnel.

Genomics Services Account for the Largest Service Share

Genomics services are projected to hold 38.4% of the market in 2026. DNA and RNA sequencing workflows remain central to target discovery, biomarker studies, translational research, and precision-medicine programs.

Genomics laboratories increasingly combine sample preparation, sequencing, quality control, data processing, and interpretation. This integrated approach can reduce handoffs between laboratory and analytical teams and provide research sponsors with a more defined workflow.

Next-generation sequencing is similarly central to the technology landscape. NGS is projected to account for 42.1% of the market in 2026, supported by its application across whole-genome sequencing, targeted panels, exome studies, transcriptomics, and other high-throughput workflows.

Direct Contracts Shape Buyer-Lab Relationships

Direct service contracts are projected to account for 30.6% share in 2026. Omics projects frequently involve customized sample requirements, assay specifications, data formats, turnaround expectations, quality controls, and intellectual-property provisions.

Long-term research agreements and project-based contracts provide additional routes for outsourcing. Laboratory service networks, online submission platforms, channel partners, and research collaborations also form part of the market.

For pharmaceutical and biotechnology buyers, supplier evaluation increasingly extends beyond sequencing capacity. Sample handling, platform validation, bioinformatics capability, data security, turnaround time, and consistency across repeat studies can influence laboratory selection.

Sample Quality and Data Interpretation Remain Challenges

The market faces operational and technical constraints despite increasing demand. Sample quality and pre-analytical consistency represent a key restraint because poor inputs can compromise results before sequencing or assay execution begins.

Data interpretation is another challenge. High-throughput omics workflows generate large datasets that require specialized bioinformatics expertise, storage infrastructure, and analytical pipelines. Buyers without internal computational capacity may therefore prefer service providers offering laboratory work together with data interpretation.

Privacy requirements surrounding human genomic information can further complicate projects involving multiple sites or cross-border sample movement.

Shambhu Nath Jha, Sr. Consultant at Fact.MR, states:

“Omics lab services are valuable when they turn biological complexity into dependable project evidence. The strongest providers combine clean lab execution with interpretable data and study-level accountability.”

United States Records the Highest Listed Country CAGR

The United States is projected to grow at a 12.59% CAGR from 2026 to 2036, the highest listed country CAGR in the Fact.MR assessment. Demand is supported by pharmaceutical R&D activity, biotechnology pipelines, NIH-funded research, and an established CRO and specialty-laboratory ecosystem.

Japan is forecast to expand at 11.67% CAGR, supported by pharmaceutical research, aging-related disease studies, and demand for sequencing and interpretation. Germany is projected to grow at 10.69% CAGR, while the United Kingdom and Canada are forecast at 9.69% and 8.69%, respectively. South Korea and Australia are projected at 6.80% and 7.72%.

Opportunities in Integrated Omics and Biomarker Services

Integrated omics and analytics represent an important opportunity as research sponsors seek to connect laboratory testing with interpretation. Combining sequencing, proteomics, metabolomics, and bioinformatics can reduce handoffs and provide a broader view of biological systems.

Clinical-trial biomarker services also offer opportunities as sponsors require patient stratification, response markers, and documentation for research programs. Single-cell and multi-omics workflows provide another area for specialized service demand where higher-resolution biological analysis is required.

Competitive Landscape

The competitive landscape includes companies offering laboratory services, sequencing capabilities, analytical workflows, and outsourced research support. Key companies profiled by Fact.MR include Thermo Fisher Scientific, Eurofins Scientific, QIAGEN, Illumina, Agilent Technologies, Charles River Laboratories, BGI Genomics, and Bio-Rad Laboratories.

Competition is shaped by laboratory capabilities, sequencing capacity, data quality, bioinformatics support, turnaround time, regulatory and quality documentation, and the ability to manage recurring research programs.

Unlock Actionable Insights from the Complete Report: https://www.factmr.com/report/omics-lab-services-market

Report Scope

The Fact.MR report analyzes the omics lab services market by service type, application, end user, distribution channel, technology, and region.

The study covers genomics, transcriptomics, proteomics, metabolomics, epigenomics, single-cell and multi-omics laboratory services, including sample preparation, sequencing, assay execution, and bioinformatics support. Applications include drug discovery and development, clinical diagnostics, precision medicine, academic research, agricultural biotechnology, and environmental research.

The report covers North America, Latin America, Europe, East Asia, South Asia and Oceania, and the Middle East and Africa, with detailed country analysis for South Korea, the United States, Canada, the United Kingdom, Germany, Australia, and Japan. The forecast period extends from 2026 to 2036.

Explore More Related Studies Published by Fact.MR Research:

Adult Stem Cells Market- https://www.factmr.com/report/adult-stem-cells-market

Cuffless BP Monitor Market- https://www.factmr.com/report/cuffless-bp-monitor-market

DNA Encoded Library Market- https://www.factmr.com/report/dna-encoded-library-market

DNA Repair Drugs Market- https://www.factmr.com/report/dna-repair-drugs-market

About Fact.MR

Fact.MR is a market research and consulting firm providing market intelligence, industry analysis, and strategic insights across a broad range of sectors. Its research supports organizations in assessing market trends, demand patterns, competitive environments, emerging technologies, and commercial opportunities.

Media Contact

Fact.MR
Phone: +1 (628) 251-1583
Email: [email protected]